LENZ

FDA Accepts LENZ Therapeutics' NDA For LNZ100 To Treat Presbyopia

(RTTNews) - LENZ Therapeutics, Inc. (LENZ) Monday said that the Food and Drug Administration (FDA) has accepted the company's new drug application for LNZ100 for the treatment of presbyopia.

Prescription Drug User Fee Act (PDUFA) target action date or a decision from the regulator is expected on August 8, 2025.

The NDA submission is supported by positive data from Phase 3 CLARITY study.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags

More Related Articles

Info icon

This data feed is not available at this time.

Data is currently not available

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.